Is there a product that would better suit a particular MET Exon 14 Skipping Mutations NSCLC patient?
P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.
© 2024 MMIT